Gogia Ajay, Deo S Vs, Shukla N K, Mathur Sandeep, Sharma D N, Tiwari Akash
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Indian J Cancer. 2018 Jul-Sep;55(3):210-213. doi: 10.4103/ijc.IJC_73_18.
This study was undertaken to evaluate the clinicopathological characteristics of patients with breast cancer at our institute, a tertiary-care cancer center in northern India.
This retrospective study included all patients with breast cancer registered at our institute from January 1, 2014 to December 31, 2016. We retrieved data (demographic, baseline clinical characteristics, pathology, and treatment details) from prospectively maintained clinical case records. Patients with incomplete case records or missing baseline information were excluded.
We included 550 patients with breast cancer. The median age was 48 years (23-85). The median clinical tumor size was 5.0 cm. The TNM (AJCC-7 edition) stage distribution was stage I, 22 (4%); stage II, 182 (33%); stage III, 247 (44.9%); and stage IV, 99 (18%). Locally advanced breast cancer constituted 40% of the cases. Bone (48 [48.5%]) was the most common site for metastasis followed by lung. Infiltrating ductal carcinoma (528 [96%]) was the most common histologic subtype. Majority of patients, 325 (59%), were positive for estrogen receptor/progesterone receptor whereas 160 (29%) patients were HER2/neu positive. Triple negative breast cancer (TNBC) constituted 28% (154) of patients. In the nonmetastatic subgroup, 343 (76%) patients underwent modified radical mastectomy. Neoadjuvant chemotherapy (NACT) was given in 120 (26.6%) patients, of these 23 (19%) achieved pathological complete remission. Sequential anthracyline and taxane were used as NACT/adjuvant chemotherapy in most cases. Of the eligible patients, 48 (30%) received anti-HER2/neu therapy.
This is one of the largest comprehensive data from a single center in India. Majority of our patients are younger in age and have advanced disease. TNBC and HER2/neu positive breast cancer are more common in our population.
本研究旨在评估我院（印度北部一家三级癌症中心）乳腺癌患者的临床病理特征。
这项回顾性研究纳入了2014年1月1日至2016年12月31日在我院登记的所有乳腺癌患者。我们从前瞻性维护的临床病例记录中检索数据（人口统计学、基线临床特征、病理学和治疗细节）。排除病例记录不完整或基线信息缺失的患者。
我们纳入了550例乳腺癌患者。中位年龄为48岁（23 - 85岁）。临床肿瘤大小中位数为5.0厘米。TNM（美国癌症联合委员会第7版）分期分布为：I期22例（4%）；II期182例（33%）；III期247例（44.9%）；IV期99例（18%）。局部晚期乳腺癌占病例的40%。骨转移（48例[48.5%]）是最常见的转移部位，其次是肺。浸润性导管癌（528例[96%]）是最常见的组织学亚型。大多数患者，325例（59%）雌激素受体/孕激素受体呈阳性，而160例（29%）患者HER2/neu呈阳性。三阴性乳腺癌（TNBC）占患者的28%（154例）。在非转移性亚组中，343例（76%）患者接受了改良根治性乳房切除术。120例（26.6%）患者接受了新辅助化疗（NACT），其中23例（19%）实现了病理完全缓解。在大多数情况下，序贯蒽环类药物和紫杉烷被用作NACT/辅助化疗。在符合条件的患者中，48例（30%）接受了抗HER2/neu治疗。
这是来自印度单一中心的最大规模综合数据之一。我们的大多数患者年龄较轻且患有晚期疾病。TNBC和HER2/neu阳性乳腺癌在我们的人群中更为常见。
